Cell Type-Specific Tumor Suppression by Ink4a and Arf in Kras-Induced Mouse Gliomagenesis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Homozygous deletion of the INK4a-ARF locus is one of the most frequent mutations found in human glioblastoma. We have previously shown that combined Ink4a-Arf loss can increase tumor incidence in both glial progenitor cells and astrocytes during mouse gliomagenesis. Here we have investigated the separate contribution of loss of each of the tumor suppressor genes in glial progenitor cells and astrocytes in Akt + Kras–induced gliomagenesis. We show that Arf is the major tumor suppressor gene in both cell types. Arf loss generated glioblastomas from both nestin-expressing glial progenitor cells and glial fibrillary acidic protein–expressing astrocytes, with a significantly higher incidence in astrocytes. Ink4a loss, on the other hand, could only significantly contribute to gliomagenesis from glial progenitor cells and the induced tumors were of lower malignancy than those seen in Arf-deficient mice. Thus, Ink4a and Arf have independent and differential tumor suppressor functions in vivo in the glial cell compartment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The role of Ink4a loss, on the other hand, could be to make cells susceptible to transformation by abolishing the fail-safe mechanism against abnormal proliferation induced by activated Kras, a response known to exist in cultured cells (15, 16).”
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566 · cited 2×
“The p19 / mice (3) and the p16 / mice (5) were crossed with the Ntv-a and Gtv-a transgenic mouse lines.”
Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568
The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis
Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H., & DePinho, R. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207074 · Cited by 224 · cited 2×
“Arf loss has been shown to cause a high frequency of tumors in a wide variety of tissue types (3, 6, 7) whereas Ink4a loss leads to a lower frequency of tumors with a more restricted tissue distribution (5, 6).”
Cited by
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
“…needed for cellular transformation, suggesting that other important cell cycle regulation pathways complement its activities in preventing gliomagenesis (Holland et al. 1998a,b; Rich et al. 2001; Sonoda et al. 2001; Bachoo et al. 2002; Huang et al. 2002; Uhrbom et al. 2002, 2005; Xiao et al. 2002).”
BackgroundCharles, N., Ozawa, T., Squatrito, M., Bleau, A.-M., Brennan, C. W., Hambardzumyan, D., & Holland, E. C. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.01.001 · Cited by 550
“Generation of PDGF-Induced Primary Glioma Cultures Neonatal Nestin tv-a (N-tva) INK4A/Arf À/À mice described previously (Uhrbom et al., 2005) were injected intracranially with DF1 chicken fibroblasts, producing RCAS-PDGF retroviral particles to generate gliomas as described previously (Shih et al.,…”
MethodSelf-citationMalignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Chen, J., McKay, R. M., & Parada, L. F. (2012) · Cell · doi:10.1016/j.cell.2012.03.009 · Cited by 527
Uroplakins in urothelial biology, function, and disease
Wu, X.-R., Kong, X.-P., Pellicer, A., Kreibich, G., & Sun, T.-T. (2009) · Kidney International · doi:10.1038/ki.2009.73 · Cited by 354
Glioma Stem Cells: A Midterm Exam
Stiles, C. D., & Rowitch, D. H. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.031 · Cited by 330
Metadata
- Authors
- Uhrbom, L., Kastemar, M., Johansson, F. K., Westermark, B., & Holland, E. C.
- Venue
- Cancer Research
- Published
- 2005-03-15
- Volume
- 65
- Issue
- 6
- Pages
- 2065-2069
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2030083720
- Cited by
- 104
- References
- 7
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell Type-Specific Tumor Suppression by Ink4a and Arf in Kras-Induced Mouse Gliomagenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-3588
- The paper
- Uhrbom, L., Kastemar, M., Johansson, F. K., Westermark, B., & Holland, E. C. (2005). Cell Type-Specific Tumor Suppression by Ink4a and Arf in Kras-Induced Mouse Gliomagenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-3588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.